Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM5A | P29375 | 1/20 | 0.57 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | MAPT | P10636 | 3/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | DAO | P14920 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | MMP13 | P45452 | 3/20 | 0.46 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.46 |
| ▸ | CDK5R1 | Q15078 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | MMP2 | P08253 | 2/20 | 0.45 |
| ▸ | MMP14 | P50281 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | GABRP | O00591 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10815601 | 0.90 | KDM5A (0.54) | KDM5AKDM5BALDH1A1MAPTL3MBTL1 | |
| SCHEMBL15269600 | 0.85 | DAO (0.57) | KDM5AKDM5BALDH1A1MAPTDAO | |
| SCHEMBL29900508 | 0.82 | MMP13 (0.65) | KDM5AKDM5BALDH1A1MAPTL3MBTL1 | |
| SCHEMBL978134 | 0.82 | MMP13 (0.65) | KDM5AKDM5BALDH1A1MAPTL3MBTL1 | |
| SCHEMBL31010837 | 0.81 | MMP13 (0.63) | KDM5AKDM5BALDH1A1MAPTL3MBTL1 | |
| Hydrochloric Acid SCHEMBL30458283 | 0.81 | MMP13 (0.63) | KDM5AKDM5BALDH1A1MAPTL3MBTL1 | |
| SCHEMBL1372751 | 0.81 | ALDH1A1 (0.59) | ALDH1A1MAPTL3MBTL1LMNAGAA | |
| SCHEMBL30086907 | 0.81 | ALDH1A1 (0.59) | ALDH1A1MAPTL3MBTL1LMNAGAA | |
| SCHEMBL15270655 | 0.79 | DAO (0.64) | KDM5AKDM5BALDH1A1MAPTL3MBTL1 | |
| SCHEMBL35211818 | 0.77 | DAO (0.62) | KDM5ADAOCDK5CDK5R1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010016846-A1 | HETEROCYCLIC MODULATORS OF TGR5 FOR TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2010-02-11 | — | — | WO | disclosed |
| US-20090054304-A1 | HETEROCYCLIC MODULATORS OF TGR5 FOR TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2009-02-26 | — | — | US | disclosed |
| EP-1226119-A4 | TYROSINE KINASE INHIBITORS | MERCK & CO INC (US) | 2003-04-09 | — | — | EP | disclosed |
| US-6479512-B1 | TO TREAT TYROSINE KINASE-DEPENDENT DISEASES AND CONDITIONS, SUCH AS ANGIOGENESIS, CANCER, TUMOR GROWTH, ATHEROSCLEROSIS, AGE RELATED MACULAR DEGENERATION, DIABETIC RETINOPATHY, INFLAMMATORY DISEASES, ETC. | MERCK & CO., INC. | 2002-11-12 | — | — | US | disclosed |
| EP-1226119-A2 | TYROSINE KINASE INHIBITORS | MERCK & CO. INC. (US) | 2002-07-31 | — | — | EP | disclosed |
| WO-2001028993-A2 | TYROSINE KINASE INHIBITORS | MERCK & CO. INC. (US) | 2001-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054304-A1 | HETEROCYCLIC MODULATORS OF TGR5 FOR TREATMENT OF DISEASE | GPBAR1, GPR119, PLAAT5 | KDM5A 1831/4885KDM5B 2116/4885ALDH1A1 2559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.